Phase I Clinical Study to Evaluate the Safety and Efficacy of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
Latest Information Update: 30 Apr 2026
At a glance
- Drugs NouvNeu 001 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors iRegene Therapeutics
Most Recent Events
- 30 Apr 2026 New trial record